Abbott Laboratories - End Period Cash Flow

Abbott Laboratories's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "End-Period-Cash-Flow" stands at 28.61 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Abbott Laboratories's third quarter result of 7.51 Billion USD for the item "End Period Cash Flow" represents an increase of 8.06 percent compared to it's second quarter result.

Also, Abbott Laboratories's third quarter result of 7.51 Billion USD for the item "End Period Cash Flow" represents a decrease of -0.62 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Abbott Laboratories's third quarter result of 28.61 Billion USD for the item "End Period Cash Flow" represents a decrease of -0.16 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 3.19 percent compared to the value the year prior.
The 1 year change in percent is 3.19.
The 3 year change in percent is -20.54.
The 5 year change in percent is 73.60.
The 10 year change in percent is 97.73.

The Serie's long term average value is 24.81 Billion United States Dollars. It's latest available value, on 09/30/2025, is 15.34 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 06/30/2014, to it's latest available value, on 09/30/2025, is +138.67%.
The Serie's change in percent from it's maximum value, on 09/30/2017, to it's latest available value, on 09/30/2025, is -40.41%.